Investigational drug · Phase 3
AOC 1044
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for DMD, Duchenne Muscular Dystrophy, Exon 44.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
4
Any phase or sponsor naming "AOC 1044"
First trial start
2022
Nov 9, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AOC 1044", any sponsor or status.
Conditions studied
As listed on its trial records.
- DMD
- Duchenne Muscular Dystrophy
- Exon 44
- Duchenne
- Muscular Dystrophies
- Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy)
- Muscular Disorders, Atrophic
- Muscular Disease
- Musculoskeletal Diseases
- Neuromuscular Diseases (NMD)
Approved drugs for the same conditions: Duchenne muscular dystrophy · Neurology · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "AOC 1044" as an intervention, largest first.
- A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 SkippingPivotal-lookingRecruiting
Avidity Biosciences, Inc.Industry
NCT07587242 · 70 participants (planned) · Start Sep 1, 2026 · Primary completion May 2029
Drug: AOC 1044; Placebo · For: Muscular Dystrophies; Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy); Muscular Disorders, Atrophic and 11 more
Sites: Westmead, Australia; Leuven, Belgium; Liège, Belgium · 20 sites in all
Avidity Biosciences, Inc.Industry
NCT05670730 · 70 participants · Start Nov 9, 2022 · Primary completion Nov 25, 2024
Drug: AOC 1044; Placebo · For: Duchenne Muscular Dystrophy; Exon 44
Sites: Little Rock, Arkansas; La Jolla, California; Palo Alto, California · 10 sites in all
- Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 SkippingActive, not recruiting
Avidity Biosciences, Inc.Industry
NCT06244082 · 39 participants · Start Jan 22, 2024 · Primary completion Apr 30, 2027
Drug: AOC 1044 · For: DMD; Duchenne Muscular Dystrophy; Duchenne and 1 more
Sites: Little Rock, Arkansas; La Jolla, California; Sacramento, California · 10 sites in all
- Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 SkippingAvailable
Avidity Biosciences, Inc.Industry
NCT07250737
Drug: delpacibart zotadirsen · For: Muscular Disorders, Atrophic; Muscular Diseases; Musculoskeletal Diseases and 6 more
Sites: Birmingham, Alabama; Little Rock, Arkansas; Irvine, California · 22 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Safety and efficacy of delpacibart zotadirsen in Duchenne muscular dystrophy mutations amenable to exon 44 skipping in the USA (EXPLORE44): a randomised, placebo-controlled, double-blind, phase 1/2 trial.
Veerapandiyan A, Eskuri J, Laverty CG, et al. · Lancet Neurol 2026
- AOC 1044 induces exon 44 skipping and restores dystrophin protein in preclinical models of Duchenne muscular dystrophy.
Etxaniz U, Marks I, Albin T, et al. · Nucleic Acids Res 2025
Also in development for DMD
- Zeleciment RostudirsenDYNE-251Phase 32 trials
Dyne Therapeutics · Duchenne Muscular Dystrophy (DMD), Muscular Dystrophy, Duchenne, Muscular Dystrophy (DMD)
- BrogidirsenNS-089, NCNP-02Phase 23 trials
NS Pharma, Inc. · Duchenne Muscular Dystrophy, Exon 44, DMD
- SAT-3247Phase 22 trials
Satellos Bioscience, Inc. · Duchenne Muscular Dystrophy, Duchenne, DMD
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.